Status: Recruiting
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.
Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoUpdated: Jun 22, 2025Locations: 1
Eligibility criteria
Patients with metastatic breast cancer underwent a liver, lung, pleural or bone...
Not available imaging (CT scan and/or PET-FdG scan) in the three months before t... [+2]